NBIX Stock Analysis — Neurocrine Biosciences
Sector: Healthcare
AI Verdict
NBIX trades at 19.4x next year's earnings with 71.6% EPS growth expected—cheap for the growth on offer if its neuroscience pipeline keeps converting.
Competitive Moat
Neurocrine Biosciences specializes in neurological and endocrine disorders, with a defensible moat built on FDA-approved treatments like Ingrezza for tardive dyskinesia and a deep pipeline targeting high-barrier CNS conditions. The company's expertise in complex neuroscience indications and regulatory know-how create high switching costs for competitors.
Summary
NBIX is on watch due to a projected 71.6% jump in earnings next year, far outpacing most of the sector.
Where It Stands
NBIX trades at 19.4x next year's earnings, below the healthcare median of 22x, with analysts expecting 71.6% EPS growth and a trailing P/E of 33.3x reflecting recent momentum.
Key Metrics
- Trailing P/E: 33.3x
- Forward P/E: 19.4x
- PEG Ratio: 0.46
- Earnings Growth: +0.7%
- Revenue Growth: +0.3%
- 52-Week High: $162.39
- 52-Week Low: $117.40
Analyst Consensus
30 Buy · 5 Hold · 0 Sell (35 analysts)
Bull Case
With a forward P/E of 19.4x and 71.6% forecasted EPS growth, NBIX is cheap for the growth you're getting if its CNS drug franchise continues to deliver.
Bear Case
If the forward P/E reverts to the sector median of 22x without delivering on 71.6% EPS growth, the stock could see a 10–15% pullback as expectations reset.
Catalyst to Watch
Watch for clinical trial readouts or new FDA approvals, as positive results could reinforce the 71.6% earnings growth narrative.